హెల్త్ కేర్ అండ్ ప్రివెన్షన్ జర్నల్

నైరూప్య

Brief Analysis on Intravenous Immunoglobulin Treatment

Richas Carlo NM

Worldwide, the coronavirus 2 causing severe acute respiratory syndrome has infected and killed an alarming number of people. For the coronavirus illness of 2019 (COVID-19), no particular treatment has been internationally standardised; nevertheless, intravenous immunoglobulin (IVIG) has occasionally been utilised as adjuvant therapy in critically ill patients with COVID-19 pneumonia. We describe a case of a 50-year-old man who had severe COVID-19 pneumonia and had received an adjuvant 5-day IVIG regimen. We avoided using intrusive respiratory support. The patient made a full recovery and was released from the hospital without additional oxygen. Patients with severe COVID-19 pneumonia may have an improved chance of survival with a large IVIG dose. We looked at research on how IVIG use might help the early stages of the disease in the current report.